EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches

Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome

(2015) Gloria Milani et al.   Oncotarget

Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner

(2013) Huafeng Xie et al.   Cell Stem Cell

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells

(2013) Zhaomei Mu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Regulation of microRNAs by epigenetics and their interplay involved in cancer

(2013) Xiaolan Liu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

EZH2 in normal and malignant hematopoiesis

(2013) K Lund et al.   LEUKEMIA

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

(2012) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

(2012) Oktay Tacar et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation

(2012) Richard L. Momparler et al.   LEUKEMIA RESEARCH

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells

(2012) Junko Kikuchi et al.   LUNG CANCER

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

(2012) Jinghui Zhang et al.   NATURE

Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia

(2012) Martin Schrappe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications

(2011) Roberta Ciarapica et al.   BMC Medicine

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

(2011) Francesco Crea et al.   Molecular Cancer

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition

(2010) Annette Hayden et al.   BREAST CANCER RESEARCH AND TREATMENT

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

(2009) Elaine Coustan-Smith et al.   LANCET ONCOLOGY

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

(2009) T. B. Miranda et al.   MOLECULAR CANCER THERAPEUTICS

DACT3 Is an Epigenetic Regulator of Wnt/β-Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications

(2008) Xia Jiang et al.   CANCER CELL

Ezh2 Requires PHF1 To Efficiently Catalyze H3 Lysine 27 Trimethylation In Vivo

(2008) K. Sarma et al.   MOLECULAR AND CELLULAR BIOLOGY